1. Home
  2. FISV vs KVUE Comparison

FISV vs KVUE Comparison

Compare FISV & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fiserv Inc.

FISV

Fiserv Inc.

N/A

Current Price

$60.37

Market Cap

34.1B

Sector

Real Estate

ML Signal

N/A

Logo Kenvue Inc.

KVUE

Kenvue Inc.

HOLD

Current Price

$19.04

Market Cap

33.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
FISV
KVUE
Founded
1984
2022
Country
United States
United States
Employees
38000
N/A
Industry
Real Estate
Specialty Chemicals
Sector
Real Estate
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
34.1B
33.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
FISV
KVUE
Price
$60.37
$19.04
Analyst Decision
Buy
Buy
Analyst Count
28
11
Target Price
$146.17
$19.64
AVG Volume (30 Days)
8.6M
49.8M
Earning Date
01-01-0001
05-19-2026
Dividend Yield
N/A
4.37%
EPS Growth
N/A
40.74
EPS
N/A
0.76
Revenue
N/A
$15,124,000,000.00
Revenue This Year
N/A
$4.07
Revenue Next Year
$4.31
$2.92
P/E Ratio
$9.94
$25.00
Revenue Growth
N/A
N/A
52 Week Low
$57.79
$14.02
52 Week High
$70.41
$25.17

Technical Indicators

Market Signals
Indicator
FISV
KVUE
Relative Strength Index (RSI) 45.77 67.31
Support Level $57.79 $16.73
Resistance Level $68.87 $22.73
Average True Range (ATR) 2.46 0.36
MACD 0.21 0.02
Stochastic Oscillator 41.69 88.66

Price Performance

Historical Comparison
FISV
KVUE

About FISV Fiserv Inc.

Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.

Share on Social Networks: